A Mini-Review of Pharmacological and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD

Rosanna Breaux, Nicholas C. Dunn, Courtney S. Swanson, Emma Larkin, James Waxmonsky and Raman Baweja

Coping Skills and Learning to Manage Emotions Readily (Calm ER) Lab, Department of Psychology, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States, 1Attention and Behavior Clinic, Department of Psychiatry and Behavioral Health, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States

Approximately a third of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) experience significant irritability; despite this, no study has reviewed whether interventions for youth with ADHD can improve irritability. This mini review sought to address this gap in the literature by discussing existing pharmacological and psychosocial interventions for irritability among children and adolescents with ADHD. A literature search was conducted in April 2021, with a total of 12 intervention articles identified (six pharmacological, one psychosocial, five combined). Studies were excluded if they did not involve an intervention, a measure of irritability, or the population was not youth with ADHD. Of these articles, two were with an ADHD only sample; seven included ADHD with comorbid disruptive behavior, disruptive mood dysregulation disorder (DMDD), or severe mood dysregulation (SMD); and three included ADHD with comorbid autism spectrum disorder (ASD). Findings suggest that central nervous system stimulants used alone or in combination with behavior therapy are effective at reducing irritability in youth with ADHD only or comorbid ADHD and DMDD/SMD. Less evidence was found for the efficacy of guanfacine and atomoxetine for youth with ADHD only or comorbid ADHD and ASD. Parent training alone or in combination with atomoxetine was found to be effective at reducing irritability in youth with comorbid ADHD and ASD. Future research assessing the efficacy of other psychosocial interventions, particularly cognitive behavioral therapy is necessary, as are randomized trials assessing intervention sequencing and intensity among youth with ADHD. Researchers are advised to utilize well-validated measures of irritability in future research.

Keywords: attention-deficit/hyperactivity disorder, irritability, intervention, mini review, medication, behavior therapy

INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent neurodevelopmental disorder characterized by inattention and/or hyperactivity/impulsivity, with three presentations based on the presence of one or both of these domains (1). Despite irritability (variation in the intensity, duration, and regulation of children's angry mood and behavior) not being a core symptom

[1] Coping Skills and Learning to Manage Emotions Readily (Calm ER) Lab, Department of Psychology, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States, 1Attention and Behavior Clinic, Department of Psychiatry and Behavioral Health, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States

INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent neurodevelopmental disorder characterized by inattention and/or hyperactivity/impulsivity, with three presentations based on the presence of one or both of these domains (1). Despite irritability (variation in the intensity, duration, and regulation of children's angry mood and behavior) not being a core symptom
of ADHD, it has been proposed that an additional presentation, one characterized by prominent irritability, should be added (2). Support for this notion comes from research suggesting that approximately a third of children and adolescents with ADHD experience clinically impairing levels of irritability (3). Additionally, irritability among youth with ADHD has been linked to concurrent and long-term depression, anxiety, suicidality, and oppositionality (3–5). Despite this, no review to date has discussed whether pharmacological and psychosocial interventions for youth with ADHD can improve comorbid irritability symptoms. Given the focus of this current special issue on ADHD with Comorbid Irritability and Recurrent Temper Outbursts and the clinical significance of comorbid irritability among youth with ADHD, the aim of this current mini review is to help address this gap in the literature by examining existing pharmacological and psychosocial intervention options used alone or in combination for irritability among youth with ADHD and a range of comorbidities.

Although no review has discussed the efficacy of interventions targeting irritability in youth with ADHD specifically, insight can be gathered from recent reviews of psychosocial and pharmacological interventions targeting irritability for youth broadly (6, 7). Kirkanski et al. (6) conducted a narrative review of psychosocial interventions for irritability in youth and found that the primary treatment methods utilized are behavioral management and cognitive behavioral therapy (CBT). However, they only discussed one small uncontrolled pilot intervention study involving youth with ADHD (8). Stringaris et al. (7) completed a review on the assessment and treatment of irritability across disorders, and highlighted that existing therapeutic methods and currently developing methods show promising results for irritability treatment. In particular, they highlighted behavioral management and CBT as promising psychosocial interventions, and discussed existing and ongoing pharmacological studies using five types of medication: lithium, selective serotonin reuptake inhibitors, stimulants, antiepileptics, and atypical antipsychotics. Although this review discusses existing treatments, it does not provide detailed information on existing research studies evaluating the effectiveness of existing interventions. Similarly, although Vidal-Ribas et al. provided a conceptual and quantitative review on the status of irritability in psychiatry, they did not discuss the effectiveness of existing treatments (9). Beyond these irritability specific review articles, several recent reviews have discussed psychosocial interventions for the treatment of emotion dysregulation (10, 11), a broader transdiagnostic factor that is related but not identical to irritability; however, these have encompassed a wide range of studies, most of which did not assess ADHD, and such reviews do not provide direct insight into which interventions are effective at reducing irritability specifically in ADHD. Given prior evidence that evidence-based treatments for ADHD are associated with smaller treatment effects for irritability than for ADHD symptoms (12), it is critical to offer a detailed synthesis of existing pharmacological and non-pharmacological interventions within this population. Further, prior reviews on the treatment of irritability have focused on pharmacological interventions in youth with Autism Spectrum Disorder (ASD), with ADHD status not systematically reported (13, 14). As such, it is not clear how these findings would generalize to youth with ADHD, especially those not meeting criteria for ASD. Given this backdrop, the current review can provide important insights into which existing treatments are effective for reducing irritability, and if the effectiveness may differ based on comorbid disorders among youth with ADHD, as well as make recommendations for important areas for future research in this at-risk clinical population.

**REVIEW PROCESS AND INCLUDED MANUSCRIPTS**

A search was conducted by the first author (RB) in April 2021. All articles were reviewed by the first and second author (RB and NC). We excluded studies that: (a) were in foreign language, (b) included only adults, (c) did not involve an intervention, (d) did not involve irritability as an efficacy outcome (e.g., only assessed irritability as an adverse event or irritability was not specifically assessed), and (e) the population did not have a primary diagnosis of ADHD or meeting ADHD diagnostic criteria was not an inclusion criteria. A total of 12 published manuscripts were identified (see Table 1). Next, we describe the efficacy of existing interventions utilized in these studies, followed by a discussion of the gaps and limitations of the existing research, and important future directions for this research.

**Pharmacological Interventions**

Six articles were identified that utilized pharmacological interventions. Two utilized CNS stimulants (12, 19), one utilized a combination of CNS stimulants and aripiprazole (16), one utilized a combination of CNS stimulants and citalopram (18), one utilized atomoxetine (15), and one utilized guanfacine (17). Four studies were an ADHD with comorbid disruptive mood dysregulation disorder (DMDD) or severe mood dysregulation (SMD) sample and two were with an ADHD with comorbid ASD sample.

In the first pharmacological intervention for youth with ADHD and comorbid DMDD/SMD, Winters et al. (19) explored the efficacy of methylphenidate (MPH; average dose 61 mg) in improving irritability in 22 children and adolescents (Mage = 12 years) using a 4-week, open-label trial. Results indicated a significant improvement in self-reported ratings of irritability ($d = 0.57, p < 0.05$). Similarly, Baweja et al. (12) explored the efficacy of CNS stimulants for 38 children (Mage = 9 years) with comorbid ADHD and DMDD during a 6-week open trial of CNS stimulant (MPH equivalents dose range of 0.71–1.03 mg/kg/day). Results indicated a significant decrease in parent-reported irritability ($d = 0.58, p < 0.05$). In the third article with an ADHD and DMDD/SMD population, Pan et al. (16) explored the effects of aripiprazole (mean dose 4.17 mg) in combination with MPH (mean dose 22.71 mg) in a 6-week, open-label trial for 51 children and adolescents (Mage = 10 years). The combination of aripiprazole and MPH resulted in significant improvements in parent-reported irritability ($d = 1.26, p < 0.001$). Finally, Towbin et al. (18) explored the utility of citalopram as an adjunctive to
### TABLE 1 | Articles targeting irritability in youth with ADHD included in the mini review (N = 12).

| References | Sample size | Age range | Clinical characteristics | Type of study | Measure | Informant | Duration | Intervention |
|------------|-------------|-----------|--------------------------|----------------|---------|-----------|----------|-------------|
| **Pharmacological interventions (n = 6)** | | | | | | | | |
| Arnold et al. (15) | 16 | 5–15 years | ADHD+ASD | RCT crossover study | ABC | Clinician | 6 weeks | Atomoxetine |
| Baweja et al. (12) | 68 | 6–12 years | ADHD+DMDD | Open trial | DBDRS | Parent | 6 weeks | CNS stimulants |
| Pan et al. (16) | 24 | 7–17 years | ADHD+DMDD | Open trial | SNAP (3 ODD items) | Parent | 6 weeks | Aripiprazole + methylphenidate |
| Scahill et al. (17) | 25 | 6–12 years | ADHD+ASD | RCT | ABC | Parent and teacher | 8 weeks | Guanfacine |
| Towbin et al. (18) | 53 | 7–17 years | ADHD + SMD | Open trial followed by RCT | CGI | Clinician | 8 weeks | Citalopram + methylphenidate |
| Winters et al. (19) | 22 | 9–15 years | ADHD+DMDD | Open trial | The irritability scale | Patient | 4 weeks | Methylphenidate |
| **Psychosocial interventions (n = 1)** | | | | | | | | |
| Waxmonsky et al. (25) | 56 | 7–12 years | ADHD + SMD | RCT | DBDRS | Parent and teacher | 11 weeks | Integrative group therapy |
| **Combined interventions (n = 5)** | | | | | | | | |
| de la Cruz et al. (21) | 579 | 7–10 years | ADHD only | RCT | SNAP (3 ODD items) | Parent and teacher | 14 months | CNS stimulants, parent training |
| Gadow et al. (22) | 168 | 6–12 years | ADHD + ODD/CD + physical aggression | Open trial | ADHD symptom checklist−4 (anger/irritability, 3 items) | Parent and teacher | 9 weeks | CNS stimulants, risperidone, parent training |
| Handen et al. (23) | 128 | 5–14 years | ADHD+ASD | RCT | ABC | Parent and teacher | 10 weeks | Atomoxetine and parent training |
| Smith et al. (24) | 88 | 5–14 years | ADHD+ASD | Open trial extension study | ABC | Parent | 24 weeks | Atomoxetine and parent training |
| Waxmonsky et al. (25) | 101 | 5–12 years | ADHD + SMD | RCT crossover study | Young Mania rating scale | Parent | 9 weeks | Methylphenidate and parent training |

ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; RCT, randomized controlled trial; ABC, Aberrant Behavior Checklist; DMDD, disruptive mood dysregulation disorder; DBDRS, Disruptive Behavior Disorder Rating Scale; CNS, central nervous system; ODD, oppositional defiant disorder; SMD, severe mood dysregulation; CGI, Clinical Global Impression’s for Chronic Severe Irritability; SNAP, Swanson Nolan and Pelham.
MPH in an 8-week, randomized controlled trial for 53 children and adolescents \(\textit{Mage} = 11\) years. Although participants were required to display SMD to be included in this study, this study was retained as all participants received a 5-week open trial of MPH to address ADHD symptoms, and 89.8% of participants had an ADHD diagnosis. For their primary outcome of the Clinical Global Impression’s for Chronic Severe Irritability, a significant decrease in irritability was found \((d = 0.60)\), with the estimated response differing between the citalopram \((35\%)\) and placebo \((6\%)\) groups \((\text{OR} = 1.70, p = 0.006)\) \((18)\).

In the first study with an ADHD and comorbid ASD population, Arnold et al. \((15)\) examined the efficacy of atomoxetine for 16 children and adolescents \((\text{Mage} = 9\) years\) during a 6-week, randomized controlled crossover trial where participants were assigned to either atomoxetine or a placebo condition. Despite Aberrant Behavior Checklist—Irritability (ABC-I) symptoms decreasing in the atomoxetine condition \((d = 0.32)\), this decrease was not significantly greater than the placebo condition \((d = 0.61)\), \(p = 0.12\). Second, Scabill et al. \((17)\) explored the effects of guanfacine in 62 children and adolescents \((\text{Mage} = 8\) years\) with ASD and ADHD symptoms using an 8-week randomized clinical trial comparing guanfacine to a placebo. Results showed that extended-release guanfacine resulted in a decrease in ABC-I \((d = 3.87)\); however, this decrease was not significantly greater than the placebo condition \((d = 1.13)\), \(p = 0.20\).

Non-pharmacological and Combined Interventions
The only non-pharmacological intervention included in this mini review provided an optimized dose of stimulant medications to both conditions prior to the 11-week randomized clinical trial \((20)\). Specifically, this study investigated whether integrative group therapy (CBT, behavioral parent training, and social cognitive training) improved ratings of irritability relative to community care for 68 children with ADHD and SMD \((\text{Mage} = 9\) years\). Findings showed that the integrative group therapy was associated with a significantly greater improvement in parent-rated irritability than stimulant community care only \((d = 0.63, p = 0.02)\). In addition to this non-pharmacological intervention study, five combined intervention studies were identified.

In an ADHD treatment study designed to assess the impact of different intensities of pharmacological and psychosocial treatments, Waxmonskey et al. \((25)\) conducted post-hoc analysis to compare the response to treatment in youth with ADHD with and without elevated levels of SMD. The study also examined the change in mood symptoms in the subset of 33 participants \((\text{Mage} = 8\) years\) with SMD. The ADHD and SMD group experienced significant improvements in irritability/aggression \((d = 1.91, p < 0.001)\). In a similar study, Gadow et al. \((22)\) assessed whether adding an augmented therapy of risperidone to parent training and stimulant medication resulted in increased improvements in irritability among 168 children with ADHD \((\text{Mage} = 8\) years\) and co-occurring ODD/conduct disorder. Results suggest that adding risperidone resulted in a significant decrease in parent-reported anger/irritability \((d = 0.19, p = 0.026)\), but not teacher-reported anger/irritability \((d = 0.17, p = 0.317)\).

Three studies compared the relative efficacy of standalone and combined interventions. First, de la Cruz et al. \((21)\) sought to determine the most effective treatment for reducing irritability, utilizing secondary analyses of the Multimodal Treatment Study of Children with ADHD. Their sample included 579 children with ADHD \((\text{Mage} = 8\) years\) who were assigned to one of four conditions in a 14-month randomized controlled trial: CNS stimulant management, behavioral management, combined CNS stimulant and behavioral management, or a community care control. Although irritability decreased over time across all conditions, the improvement was significantly greater in the CNS stimulant \((d = 0.63)\) and combined \((d = 0.82)\) groups relative to the behavioral management \((d = 0.42)\) and community comparison \((d = 0.48)\) groups. In contrast, Handen et al. \((23)\) compared the efficacy of atomoxetine and parent training used alone and in combination relative to a placebo in 128 children and adolescents \((\text{Mage} = 8\) years\) with comorbid ADHD and ASD using a 10-week randomized controlled trial. Results indicated that despite the atomoxetine and parent training group \((d = 0.68)\) and atomoxetine \((d = 0.64)\) group displaying moderate parent-reported improvements in irritability, only the parent training condition \((d = 0.96)\) resulted in a significantly greater decrease in irritability than placebo \((d = 0.51)\). No significant differences were found across groups for teacher-reported irritability. In a 24-week extension to Handen et al., \((23)\) and Smith et al. \((24)\) investigated the efficacy of continued parent training with or without atomoxetine among 117 youth \((\text{Mage} = 8\) years\). Despite large improvements from baseline to week 22 among families who received parent training \((d = 0.94)\), this improvement was only marginally larger than the group that did not receive parent training \((d = 0.62)\), \(p = 0.08\). Additionally, families in the atomoxetine and parent training condition showed a significant decrease in irritability from baseline to week 20 \((d = 0.44, p < 0.05)\), whereas there was not significant improvement in the atomoxetine only group.

DISCUSSION
Inconsistent findings regarding the efficacy of existing interventions for improving irritability among youth with ADHD were present across included studies. Some of the differences appear to differ based on comorbid conditions (ASD vs. DMDD/SMD), and types of pharmacological interventions used (CNS stimulants vs. non-stimulants). Specifically, across the four pharmacological interventions with youth with comorbid ADHD and DMDD/SMD \((12, 16, 18, 19)\), all found evidence that CNS stimulants are effective at improving irritability in children with comorbid ADHD and DMDD/SMD either when used alone \((12, 18, 19)\) or in combination with aripiprazole \((16)\). However, since these studies were all open trials, it is unclear if the observed medium to large improvements are larger than would be expected in a placebo controlled trial. These findings suggest that for youth with ADHD and comorbid DMDD/SMD, CNS stimulants can result in moderate to large improvements.
either alone or in combination with behavior therapy. Systematic titration of CNS stimulant dose using parent and teacher ratings at regular intervals has been found to lead to significant reduction in aggression and other disruptive behaviors even in youth previously failing to respond to CNS stimulant (26). Therefore, multiple attempts to optimize stimulant dose and engage families in evidence based parenting interventions appears prudent before consideration of adjunctive medications, with potentially more problematic tolerability profiles such as antipsychotics. Unfortunately, almost half of youth with an ADHD diagnosis are not prescribed CNS stimulants prior to the use of antipsychotics (27).

A somewhat different pattern of efficacy for other approved ADHD medications (atomoxetine or guanfacine) was found for youth; however it is important to note these medications, unlike the CNS stimulants, were examined in youth with comorbid ADHD and ASD. Specifically, the two pharmacological and one combined intervention studies failed to find evidence of either atomoxetine or guanfacine being effective at significantly reducing irritability relative to a placebo (15, 17, 23); whereas, there was evidence that parent training alone may significantly improve irritability among youth with ADHD and ASD. Consistent with these findings, an extension trial found that youth in the atomoxetine and parent training condition, but not youth in the atomoxetine condition, showed significant decreases in irritability (24). Results suggest that for youth with ADHD and comorbid ASD, parent training is necessary to target youth irritability. However, no studies reporting irritability as an outcome among youth with comorbid ADHD and ASD utilized CNS stimulants. CNS stimulants significantly reduce ADHD symptoms in youth with ASD (28). Given the high rates of ADHD and irritability in youth with ASD (29, 30), it would be imperative to systematically explore the impact of CNS stimulants on irritability in youth with both disorders. In conducting such research, it will be critical to closely monitor adverse events, given evidence of a greater likelihood for side effects (e.g., obsessional behavior, and dysphoria) in youth with comorbid ADHD and ASD compared to youth with ADHD only (31).

**Gaps of Existing Intervention Research**

The literature targeting irritability among youth with ADHD is limited by a large reliance on small sample sizes and open trials. In the current mini review, only four studies had a sample of more than 100, with only one of these having a sample larger than 200 (see Table 1). Further, five of the 12 articles were open trials (12, 16, 19, 22, 24), with such methodology being particularly common among studies of youth with comorbid ADHD and DMDD/SMD. As such, large randomized trials examining the efficacy of CNS stimulants used alone or in combination with behavioral therapy or an adjunctive pharmacological intervention are needed among youth with comorbid ADHD and DMDD/SMD. In fact, only two RCTs exist among youth with comorbid ADHD and DMDD/SMD, one was the psychosocial intervention study (20) and the other involved participation in a Summer Treatment Program and assessing various dosage of a combination of CNS stimulants and parent training (25). As such, no pharmacological intervention study has systematically assessed the impact of CNS stimulants in this population; of note, Towbin et al. (18) conducted an RCT assessing the efficacy of citalopram as an adjunct to CNS stimulants and found evidence of added benefits when combining a SSRI with a CNS stimulant.

Of the seven studies utilizing a randomized trial, two compared a pharmacological intervention (atomoxetine and guanfacine) to a placebo (15, 17), one compared a combined psychosocial and pharmacological intervention (CNS stimulants and Integrative Group Therapy) to CNS stimulants only (20), one compared CNS stimulants alone to CNS stimulants with a citalopram adjunctive (18), two compared psychosocial and pharmacological interventions alone and in combination to a placebo (21, 23), and one compared varying intensities of both behavior therapy and CNS stimulants in combination (25). Of these, three were with youth with comorbid ADHD and ASD samples, as was previously mentioned, none of these studies examined the use of CNS stimulants in this population, a critical gap in the literature. Furthermore, there is a particular dearth of data for the capacity of alpha agonists to improve irritability among youth with ADHD, which is surprising given their frequent use for youth with ADHD (32). The inconsistency in use of a placebo vs. active control also limits our ability to make direct comparisons across these studies. Of note, none of the existing studies compared the relative efficacy of various pharmacological interventions used alone (e.g., CNS stimulants vs. atomoxetine).

Further, given the evidence of CNS stimulants alone or in combination with parent training for reducing irritability, it will be critical for future research to utilize cutting-edge research methodologies to assess intensity and sequencing of these interventions to improve outcomes and reduce costs. For example, Sequential Multiple Assignment Randomized Trial (33) designs allow for systematic assessment of independent and combined interventions, and ordering of such interventions, as well as for examination of optimal adaptive intervention approaches by individualizing sequences of treatments. Research utilizing this methodology for assessing CNS stimulants and behavior therapy for the treatment of ADHD symptoms suggests that the optimal and most cost effective sequence is to begin with low intensity behavioral therapy followed by adjunctive medication in those with persistent impairment (34), and that adding behavioral therapy after medication, results in poorer attendance for therapy sessions, resulting in reduced efficacy for this sequence (35). Future research should implement similar methodologies examining improvements in irritability specifically among youth with ADHD, and whether treatment sequencing and intensity differ based on comorbid conditions.

Existing studies are also limited by inconsistencies in measurement of irritability which until recently was primarily measured only as side effect of ADHD medications, using largely unstructured spontaneous report. Specifically, only six of the included studies utilized an established scale for irritability, with four using the ABC-I subscale (15, 17, 23, 24), one utilizing the Clinical Global Impression focused on irritability which was generated based on a semi-structured diagnostic interview (25), and one utilizing youth self-report on The Irritability
Scale (22). In contrast, five of the studies created irritability composites based on ODD items from rating scales for disruptive behavior, including the Swanson Nolan and Pelham version IV scale, the Disruptive Behavior Disorder Rating Scale, and the ADHD Symptom Checklist (12, 16, 20–22). Further, one utilized a measure of mania to assess irritability, specifically the Young Mania Rating Scale (25). Surprisingly, none employed the Affective Reactivity Index (ARI) (36), which has well-established psychometrics in pediatric populations. As such, we recommend that future research assessing interventions for irritability among youth with ADHD utilize well-validated measures, such as the ABC-I and ARI, as well as consider integrating multiple informants vs. sole reliance on parent report. Such an approach was only used in one of the included studies in this review (18).

Relatedly, several studies were excluded from the review due to only examining irritability as a side effect/adverse event (37, 38).

Interestingly, only one of the psychosocial or combined interventions examined psychosocial interventions other than parent training, with this study utilizing an integrative group therapy that involved behavioral parent training along with CBT and social cognitive training. There is evidence from reviews of psychosocial interventions that CBT is effective for reducing irritability in youth across diagnoses that CBT is effective for these purposes (39). CBT has been found to be effective for improving depression in teens with comorbid ADHD (40) and CBT is being adapted to specifically target irritability in youth (11, 41). As such, exploring the efficacy of CBT as a standalone intervention and add on to pharmacological interventions among adolescents with ADHD is a critical area for future research. It will be important for such research to assess whether efficacy for irritability generalize across comorbid psychiatric disorders in this population.

**CONCLUSION**

This mini review addresses an important gap in the literature by discussing the existing pharmacological and psychosocial interventions targeting irritability among youth with ADHD. Findings suggest that CNS stimulants used alone or in combination with behavioral therapy (e.g., parent training) are effective at reducing irritability in youth with ADHD only or comorbid ADHD and DMDD/SMD. Less evidence was found for the efficacy of alpha agonists and atomoxetine, with existing studies focusing on youth with comorbid ASD. One study found evidence for benefits of adding a selective serotonin reuptake inhibitor (citalopram) to MPH for reducing irritability in youth with ADHD and DMDD/SMD. Parent training alone or in combination with atomoxetine was found to be effective at reducing irritability in youth with comorbid ADHD and ASD. Future research assessing the efficacy of other psychosocial interventions, particularly CBT is necessary, as are randomized trials with large samples using well-validated scales designed to measure irritability that assess intervention sequencing and intensity among youth with ADHD.

**AUTHOR CONTRIBUTIONS**

RBr conducted the review of the literature and took lead on drafting this manuscript. ND reviewed all included articles and assisted with writing the manuscript. CS, JW, and RBa assisted with writing and revising the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

The authors would like to thank the Virginia Tech Open Access Subvention Fund for covering the processing charges of this article.

**ACKNOWLEDGMENTS**

This authors would like to thank Annah Cash and Delshad Shroff for assisting with this review.

**REFERENCES**

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Arlington, VA: American Psychiatric Association (2013).
2. Karalunas SL, Gustafsson HC, Fair D, Musser ED, Nigg JT. Do we need an irritable subtype of ADHD? Replication and extension of a promising temperament profile approach to ADHD subtyping. *Psychol Assess.* (2019) 31:236–47. doi: 10.1037/pas0000064
3. Eyre O, Langley K, Stringaris A, Leibenluft E, Collishaw S, Thapar A. Irritability in ADHD: associations with depression liability. *J Affect. Disord.* (2017) 215:281–7. doi: 10.1016/j.jad.2017.03.050
4. Eyre O, Riglin L, Leibenluft E, Stringaris A, Collishaw S, Thapar A. Irritability in ADHD: association with later depression symptoms. *Eur Child Adolesc Psychiatry.* (2019) 28:1375–84. doi: 10.1007/s00787-019-01303-x
5. Levy T, Kronenberg S, Croesbe J, Schachar RJ. Attention-deficit/hyperactivity disorder (ADHD) symptoms and suicidality in children: the mediating role of depression, irritability and anxiety symptoms. *J Affect. Disord.* (2020) 265:200–6. doi: 10.1016/j.jad.2020.01.022
6. Kircanski K, Clayton ME, Leibenluft E, Brotman MA. Psychosocial treatment of irritability in youth. *Curr Treat Options Psychiatry.* (2018) 5:129–40. doi: 10.1007/s44051-018-0141-5
7. Stringaris A, Vidal-Ribas P, Brotman MA, Leibenluft E. Practitioner review: definition, recognition, and treatment challenges of irritability in young people. *J Child Psychol Psychiatry.* (2018) 59:721–39. doi: 10.1111/jcpp.12823
8. Waxmonsky JG, Wymbs FA, Pariseau ME, Belin PJ, Waschbusch DA, Babocsai L, et al. A novel group therapy for children with ADHD and severe mood dysregulation. *J Affect. Disord.* (2013) 17:527–41. doi: 10.1177/1087054711433423
9. Vidal-Ribas P, Brotman MA, Valdivieso I, Leibenluft E, Stringaris A. The status of irritability in psychiatry: A conceptual and quantitative review. *J Can Acad Child Adolesc Psychiatry.* (2016) 55:556–70. doi: 10.1016/j.jaac.2016.04.014
10. Eadeh HM, Breaux R, Nikolas MA. A meta-analytic review of emotion regulation focused psychosocial interventions for adolescents. *Clin Child Fam Psychol Rev.* (2021) Advanced Online Publication. doi: 10.1007/s10567-021-00362-4
11. Waxmonsky JG, Baweja R, Bansal PS, Waschbusch DA. A review of the evidence base for psychosocial interventions for the treatment of emotion dysregulation in children and adolescents. *Child Adolesc Psychiatry Clin.* (2021) 30:573–94. doi: 10.1016/j.chc.2021.04.008
12. Baweja R, Belin PJ, Humphrey HH, Babocsai L, Pariseau ME, Waschbusch DA, et al. The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/hyperactivity disorder and disruptive mood disorder dysregulation across home and school. *J Child Adolesc Psychopharmacol.* (2016) 26:154–63. doi: 10.1089/cap.2015.0053
13. Elze D, Lalani Z. Review of the pharmacotherapy of irritability of autism. *J Can Acad Child Adolesc Psychiatry.* (2012) 21:130–46.
14. Fung LK, Mahajan R, Nozolillo A, Bernal P, Krasner A, Jo B, et al. Pharmacologic treatment of severe irritability and problem behaviors in...
autism: a systematic review and meta-analysis. *Pediatrics*. (2016) 137:5124–35. doi: 10.1542/peds.2015-2851K

15. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. *J Am Acad Child Adoles Psychiatry*. (2006) 45:479–86. doi: 10.1097/01.chi.0000231976.26719.2a

16. Pan PY, Fu AT, Yeh CB. Aripiprazole/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: an open-label study. *J Child Adolesc Psychopharmacol*. (2018) 28:862–9. doi: 10.1097/CJP.0000000000000668

17. Sehail L, McCracken JT, King BH, Rockhill C, Shah B, Polite L, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. *Am J Psychiatry*. (2015) 172:1197–206. doi: 10.1176/appi.ajp.2015.15010055

18. Towbin K, Vidal-Ribas P, Brotman MA, Pickles A, Miller KV, Kaiser A, et al. A double-blind randomized placebo-controlled trial of citalopram adjunctive to stimulant medication in youth with chronic severe irritability. *J Am Acad Child Adoles Psychiatry*. (2020) 59:350–61. doi: 10.1016/j.jaac.2019.05.015

19. Winters DE, Fukui S, Leibenua E, Hulvershorn LA. Improvements in irritability with open-label methylphenidate treatment in youth with comorbid attention deficit/hyperactivity disorder and disruptive mood dysregulation disorder. *J Child Adolesc Psychopharmacol*. (2018) 28:298–305. doi: 10.1097/CJP.0000000000000724

20. Waxmonsky JG, Waschbusch DA, Belin P, Li T, Babocsai L, Humphrey H, et al. A randomized clinical trial of an integrative group therapy for children with severe mood dysregulation. *J Am Acad Child Adoles Psychiatry*. (2016) 55:196–207. doi: 10.1016/j.jaac.2015.12.011

21. de la Cruz LF; Simonoff E, McHugh JG, Halperin JM, Arnold LE. Stringaris A. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). *J Am Acad Child Adoles Psychiatry*. (2015) 54:62–70. doi: 10.1016/j.jaac.2014.10.006

22. Gadow KD, Arnold LE, Molina BS, Findling RL, Bukstein OG, Brown NV, et al. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. *J Am Acad Child Adoles Psychiatry*. (2014) 53:948–59. doi: 10.1016/j.jaac.2014.05.008

23. Handen BL, Aman MG, Arnold LE, Hyman SL, Tunuluwir RV, Lecavalier L, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. *J Am Acad Child Adoles Psychiatry*. (2015) 54:905–15. doi: 10.1016/j.jaac.2015.08.013

24. Smith T, Aman MG, Arnold LE, Silverman LB, Lecavalier L, Holloway J, et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. *J Am Acad Child Adoles Psychiatry*. (2016) 55:868–76. doi: 10.1016/j.jaac.2016.06.015

25. Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O’Connor B, Majumdar A, et al. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. *J Child Adolesc Psychopharmacol*. (2018) 18:573–88. doi: 10.1089/cap.2018.0085

26. Blader JC, Pliszka SR, Kafantaris V, Foley CA, Carlson GA, Crowell IA, et al. Stepped treatment for attention-deficit/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization. *J Am Acad Child Adoles Psychiatry*. (2021) 60:236–51. doi: 10.1016/j.jaac.2019.12.009

27. Sultan RS, Wang S, Crystal S, Olfson M. Antipsychotic treatment among children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. *Child Care Health Dev*. (2006) 32:575–83. doi: 10.1111/j.1532-2141.2006.00631.x

28. Froehlich TE. Comparison of medication treatments for preschool children with ADHD: a first step toward addressing a critical gap. *JAMA*. (2021) 325:2049–50. doi: 10.1001/jama.2021.5603

29. Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research. *Transl Behav Med*. (2014) 4:260–74. doi: 10.1007/s13142-014-0265-0

30. Page TF, Pelham WE, III, Fabiano GA, Greiner AR, Gnagy EM, Hart KC, et al. Comparative cost analysis of sequential, adaptive, behavioral, pharmacological, combined treatments for childhood ADHD. *J Clin Child Adoles Psychol*. (2016) 45:416–27. doi: 10.1080/15374416.2015.1055859

31. Santosh PJ, Baird G, Pitipatrasit N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. *Child Care Health Dev*. (2006) 32:575–83. doi: 10.1111/j.1532-2141.2006.00631.x

32. Stringaris A, Goodman R, Ferdinando S, Razdan V, Muhrer E, Leibenua E, et al. The affective reactivity index: a concise irritability scale for clinical and research settings. *J Child Psychol Psychiatry*. (2012) 53:1109–17. doi: 10.1111/j.1469-7610.2012.02561.x

33. Waxmonsky JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. *J Clin Psychiatry*. (2010) 71:1535–51. doi: 10.4088/JCP.09m05496pub

34. Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS. Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). *Child Adolesc Psychiatry Mental Health*. (2008) 2:1–10. doi: 10.1186/1753-2000-2-11

35. Evans SC, Weisz JR, Carvalho AC, Garibaldi PM, Bearman SK, Chorpita BE, et al. Effects of standard and modular psychotherapies in the treatment of youth with severe irritability. *J Consult Clin Psychol*. (2020) 88:255–68. doi: 10.1037/ccp0000456

36. Kratochvil CJ, May DE, Silva SG, Madaan V, Puamula SE, Curry JF, et al. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. *J Child Adoles Psychopharmacol*. (2009) 19:519–27. doi: 10.1080/2008.01143

37. Kircanski K, Craske MG, Averbeck BB, Pine DS, Leibenluft E, Brotman MA. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. *J Am Acad Child Adoles Psychiatry*. (2015) 54:62–70. doi: 10.1016/j.jaac.2014.10.006

Conflict of Interest: In the past three years, JW has received research funding from Supernus and served as a consultant for Adlon Therapeutics and Intracellular Therapies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Breaux, Dunn, Swanson, Larkin, Waxmonsky and Baweja. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.